14102 studies
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as tirzepatide (Mounjaro), are widely used for type 2 diabetes and obesity, but their effects on drug metabolism and immune regulation remain areas of concern. We report a 64-year-old male wi…
INTRODUCTION: Cardiovascular diseases remain the leading cause of mortality worldwide. Tirzepatide is approved for the treatment of type 2 diabetes mellitus and overweight and is increasingly used. The adverse effects with tirzepatide may not be dise…
BACKGROUND: The use of ChatGPT in healthcare is still in its early stages; however, it has the potential to become a cornerstone in modern healthcare systems. This study aims to assess the accuracy of output of ChatGPT compared with those of CareNote…
BACKGROUND: Despite therapeutic benefits, discontinuation of tirzepatide is common in randomized controlled trials (RCTs) due to adverse events (AEs) and other causes. No previous systematic reviews have explored the reasons for discontinuing tirzepa…
Tirzepatide is a unimolecular dual agonist of both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, which is developed as once-weekly subcutaneous injection. It has been developed in two huge research…
OBJECTIVE: Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a pot…
INTRODUCTION: Tirzepatide, an anti-obesity medication, demonstrated significant weight loss efficacy in the SURMOUNT-1 randomized controlled trial. This analysis evaluates the cost-efficiency of tirzepatide in the UK by linking clinical outcomes to d…
BACKGROUND: OSA is a prevalent chronic condition linked to obesity that is associated with increased risks of cardiovascular and kidney disease. Although weight loss can improve OSA outcomes, additional effective therapeutic options are needed. Tirze…
BACKGROUND: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the only type 2 diabetes medications that reduce cardiovascular disease and death, yet their availability in Medicaid is unc…
As obesity is increasing in prevalence and its associated morbidity and mortality are escalating worldwide, medications like tirzepatide are frequently used for weight loss benefits in patients without diabetes. Tirzepatide has rarely been associated…
Bariatric surgery has long been the most effective intervention for obesity, providing significant and durable weight loss, with procedures like sleeve gastrectomy and gastric bypass achieving 10-year total weight loss (TWL) rates of 23.4% and 26.9%,…
Tirzepatide is an approved drug that is used to treat type 2 diabetes. Tirzepatide is a peptide comprised of 39 amino acids and activates glucose-dependent insulinotropic polypeptide receptors (GIPR) and glucagon-like peptide-1 receptors (GLP-1R). Vi…
Glucagon-like peptide-1 receptor agonist (GLP-1RA) has attracted attention owing to its hypoglycemic and weight-loss effects, and various dosage forms are available in the market. Recently, glucose-dependent insulin secretion-stimulating polypeptide…